(-)-Ropivacaine-d7 (hydrochloride) (Synonyms: (S)-Ropivacaine-d7) |
| Catalog No.GC46248 |
An internal standard for the quantification of (–)-ropivacaine
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1217667-10-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
(-)-Ropivacaine-d7 is intended for use as an internal standard for the quantification of (-)-ropivacaine by GC- or LC-MS. (-)-Ropivacaine is a potent and reversible blocker of sodium channels in nerve fibers.1 In vivo, (-)-ropivacaine induces complete impairment of proprioception, motor function, and nociception in the hindleg of rats when 100 μL of an 8 mM solution is injected percutaneously into the sciatic nerve.2 (-)-Ropivacaine depresses myocardial contractile force in isolated rat hearts less potently than (±)-ropivacaine, as well as (-)- and (±)-bupivacaine .3 Formulations containing (-)-ropivacaine have been used as local anesthetics during surgery and childbirth.
1.Hansen, T.G.Ropivacaine: A pharmacological reviewExp. Rev. Neurother.4(5)781-791(2004) 2.Sinnott, C.J., and Strichartz, G.R.Levobupivacaine versus ropivacaine for sciatic nerve block in the ratReg. Anesth. Pain Med.28(4)294-303(2003) 3.Pinotti, M.F., Hepner, A., Campos, D.H., et al.Myocardial contractility impairment with racemic bupivacaine, non-racemic bupivacaine and ropivacaine. A comparative studyActa Cir. Bras.30(7)484-490(2015)
Average Rating: 5 (Based on Reviews and 22 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *